Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice

Frontiers in Medicine - Tập 7
Kateryna Pierzynowska1,2,3, Aditi Deshpande4, Nadia M. Mosiichuk5, Robert Terkeltaub6, Paulina Szczurek7, Eduardo Salido8, Stefan Pierzynowski9,2,3, Danica Grujić4
1Department of Animal Physiology, Kielanowski Institute of Animal Nutrition and Physiology Polish Academy of Sciences, Jabłonna, Poland
2Department of Biology, Lund University, Lund, Sweden
3SGP + Group, Trelleborg, Sweden
4Allena Pharmaceuticals, Newton, MA, United States
5Department of Biochemistry and Biotechnology, Vasyl Stefanyk Precarpathian National University, Ivano-Frankivsk, Ukraine
6VA Medical Center, University of California, San Diego, La Jolla, CA, United States
7Department of Animal Nutrition and Feed Sciences, National Research Institute of Animal Production, Balice, Poland
8Hospital Universitario de Canarias, Universidad La Laguna & Center for Rare Diseases (CIBERER), Tenerife, Spain
9Department of Biology, Institute Rural Medicine, Lublin, Poland

Tóm tắt

Limitations in efficacy and/or tolerance of currently available urate-lowering therapies (ULTs), such as oral xanthine oxidase inhibitors, uricosurics, and intravenous uricase agents contribute to the development of refractory gout. Renal excretion is the major route of uric acid elimination, but the intestinal tract plays an increasingly recognized role in urate homeostasis, particularly in chronic kidney disease (CKD) in which the renal elimination of urate is impaired. We targeted intestinal degradation of urate in vivo with ALLN-346, an orally administered, engineered urate oxidase, optimized for proteolytic stability, and activity in the gut. We tested ALLN-346 in uricase/urate oxidase deficient mice (URKO mice) with severe hyperuricemia, hyperuricosuria, and uric acid crystalline obstructive nephropathy. A total of 55 male and female URKO mice were used in the two consecutive studies. These seminal, proof-of-concept studies aimed to explore both short- (7-day) and long-term (19-day) effects of ALLN-346 on the reduction of plasma and urine urate. In both the 7- and 19-day studies, ALLN-346 oral therapy resulted in the normalization of urine uric acid excretion and a significant reduction of hyperuricemia by 44 and 28% when therapy was given with food over 24 h or was limited for up to 6 h, respectively. Fractional excretion of uric acid (FEUA) was normalized with ALLN-346 therapy. Oral enzyme therapy with engineered urate oxidase (ALLN-346) designed to degrade urate in the intestinal tract has the potential to reduce hyperuricemia and the renal burden of filtered urate in patients with hyperuricemia and gout with and without CKD.

Từ khóa


Tài liệu tham khảo

Khanna, 2012, American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia, Arthritis Care Res, 64, 1431, 10.1002/acr.21772

Zhu, 2011, Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007–2008, Arthritis Rheum, 63, 3136, 10.1002/art.30520

Terkeltaub, 2010, Update on gout: new therapeutic strategies and options, Nat Rev Rheumatol, 6, 30, 10.1038/nrrheum.2009.236

Cicerello, 2018, Uric acid nephrolithiasis: an update, Urologia, 85, 93, 10.1177/0391560318766823

Singh, 2008, Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans, Ann Rheum Dis, 67, 1310, 10.1136/ard.2007.081604

Jin, 2012, Uric acid, hyperuricemia and vascular diseases, Front Biosci, 17, 656, 10.2741/3950

Stamp, 2013, Gout and its comorbidities: implications for therapy, Rheumatology, 52, 34, 10.1093/rheumatology/kes211

Gustafsson, 2013, The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality, BMC Nephrol, 14, 164, 10.1186/1471-2369-14-164

Joosten, 2020, Asymptomatic hyperuricaemia: a silent activator of the innate immune system, Nat Rev Rheumatol, 16, 75, 10.1038/s41584-019-0334-3

Reginato, 2012, The genetics of hyperuricaemia and gout, Nat Rev Rheumatol, 8, 610, 10.1038/nrrheum.2012.144

Perez-Ruiz, 2002, Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output, Arthritis Rheum, 47, 610, 10.1002/art.10792

Sorensen, 1965, Role of the intestinal tract in the elimination of uric acid, Arthritis Rheum, 8, 694, 10.1002/art.1780080429

Mandal, 2015, The molecular physiology of uric acid homeostasis, Annu Rev Physiol, 77, 323, 10.1146/annurev-physiol-021113-170343

Hyndman, 2016, Urate handling in the human body, Curr Rheumatol Rep, 18, 34, 10.1007/s11926-016-0587-7

Bhatnagar, 2016, Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling, Clin Kidney J, 9, 444, 10.1093/ckj/sfw010

Dalbeth, 2019, Gout, Nat Rev Dis Primers, 5, 69, 10.1038/s41572-019-0115-y

Garg, 2005, Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial, Arthritis Rheum, 52, 290, 10.1002/art.20781

Ohno, 2009, Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients, Intern Med, 48, 415, 10.2169/internalmedicine.48.1817

Nigam, 2018, The systems biology of uric acid transporters: the role of remote sensing and signaling, Curr Opin Nephrol Hypertens, 27, 305, 10.1097/MNH.0000000000000427

Gutmann, 2005, Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract, Biochem Pharmacol, 70, 695, 10.1016/j.bcp.2005.05.031

Nakayama, 2011, ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans, Nucleosides Nucleotides Nucleic Acids, 30, 1091, 10.1080/15257770.2011.633953

Yano, 2014, Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease, Clin Exp Nephrol, 18, 50, 10.1007/s10157-013-0806-8

Takada, 2014, ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion, Nucleosides Nucleotides Nucleic Acids, 33, 275, 10.1080/15257770.2013.854902

Matsuo, 2013, Common dysfunctional variants in ABCG2 are a major cause of early-onset gout, Sci Rep, 3, 2014, 10.1038/srep02014

Woodward, 2015, ABCG2: the molecular mechanisms of urate secretion and gout, Am J Physiol Renal Physiol, 309, F485, 10.1152/ajprenal.00242.2015

Vargas-Santos, 2017, Management of gout and hyperuricemia in CKD, Am J Kidney Dis, 70, 422, 10.1053/j.ajkd.2017.01.055

Ramirez-Sandoval, 2018, Treatment of hyperuricemia in chronic kidney disease, Contrib Nephrol, 192, 135, 10.1159/000484288

Wu, 1994, Hyperuricemia and urate nephropathy in urate oxidase-deficient mice, Proc Natl Acad Sci USA, 91, 742, 10.1073/pnas.91.2.742

Ichida, 2012, Decreased extra-renal urate excretion is a common cause of hyperuricemia, Nat Commun, 3, 764, 10.1038/ncomms1756

Sorensen, 1975, Origin and extrarenal elimination of uric acid in man, Nephron, 14, 7, 10.1159/000180432

Lu, 2018, Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders, Kidney Int, 93, 69, 10.1016/j.kint.2017.04.031

Liu, 2017, Patients with gout differ from healthy subjects in renal response to changes in serum uric acid, Joint Bone Spine, 84, 183, 10.1016/j.jbspin.2016.04.007

Tan, 2017, Uric acid transporter inhibitors for gout, ADMET DMPK, 5, 59, 10.5599/admet.5.2.387

Stiburkova, 2019, The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout I pediatric-onset patients, Arthritis Res Ther, 21, 77, 10.1186/s13075-019-1860-8

Yun, 2017, Intestinal tract is an important organ for lowering serum uric acid in rats, PLoS ONE, 12, e0190194, 10.1371/journal.pone.0190194

Preitner, 2009, Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy, Proc Natl Acad Sci USA, 106, 15501, 10.1073/pnas.0904411106

Nemali, 1988, Comparison of constitutive and inducible levels of expression of peroxisomal β-oxidation and catalase genes in liver and extrahepatic tissues of rat, Cancer Res, 48, 5316

Guttmann, 2017, Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations, Ther Adv Drug Saf, 8, 379, 10.1177/2042098617727714

Thông tin
Thông tin xuất bản

Frontiers in Medicine

Tập 7

Thông tin tác giả